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Abstract: Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the 
HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast 
cancer, and has since led to significant improvements in the overall prognosis for patients with HER2-positive metastatic disease. The 
favourable benefit/risk profile associated with palliative trastuzumab has been demonstrated in a number of clinical trials that examined 
trastusumab as monotherapy or in combination with chemotherapy, endocrine therapy and other HER2 targeted agents. The clinical 
benefits of trastuzumab, however should also be examined within the context of its significant drug acquisition costs. This review 
highlights the significant findings from the landmark clinical trials of trastuzumab for metastatic HER2-positive breast cancer, and the 
potential “value for money” associated with its use in clinical practice.
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Introduction
Human epidermal growth factor receptor 2 (HER2) 
protein  over-expression  and/or  gene  amplifica-
tion are observed in approximately 20% of breast 
cancers, and are associated with more aggressive 
natural  history  compared  with  HER2  negative 
counterparts.1  Trastuzumab  (Herceptin®)  was  the 
first  targeted  therapy  approved  by  the  FDA  in 
September 1998 for HER2-positive breast cancer, 
and has since led to significant improvements in the 
overall prognosis for patients with HER2-positive 
metastatic disease.2 It is a recombinant humanized 
monoclonal  antibody  that  selectively  targets  the 
extra-cellular domain of the HER2 receptor.3 Breast 
cancers  with  HER2  protein  over-expression  (3+) 
and/or gene amplification by immunohistochemistry 
(IHC) and fluorescence in situ hybridization (FISH) 
respectively derive large benefits from trastuzumab 
therapy, while those with no or weak (0 or 1+) pro-
tein  expression  and  non-amplified  gene  copy  do 
not.4 Trastuzumab is also associated with signifi-
cant drug acquisition costs that should be examined 
within  the  context  of  all  its  associated  benefits.5 
We  herein  review  the  landmark  clinical  trials  of 
palliative  trastusumab,  and  the  potential  “value 
for money” associated with its use, for metastatic 
HER2-positive breast cancer.
Mechanism of Action, 
pharmacokinetics and precautions
HER2  is  a  185  KD  transmembrane  glycoprotein 
receptor  with  intracellular  tyrosine  kinase  activ-
ity.6 It is one of four well characterized epidermal 
growth  factor  receptors  (EGFR)  that  are  involved 
in the activation of subcellular signal transduction 
pathways controlling epithelial cell growth, differen-
tiation and possibly angiogenesis.7–10 It is normally 
expressed  at  low  levels  in  a  variety  of  epithelial 
cell types including breast duct epithelium, and is 
over-expressed in approximately 20% of breast can-
cers.11 HER2 receptor over-expression on the surface 
of tumor cells results in a constitutively activated 
HER2 signaling pathway, and worse outcomes.1 Tras-
tuzuamb selectively targets the extra-cellular domain 
of the HER2 receptor, and has been shown to inhibit 
the  proliferation  of  HER2-positive  tumor  cells  in 
both in-vitro and in-vivo studies by down regulating 
the HER2 receptors.3 Other possible mechanisms of 
action include an antibody-dependent cell-mediated 
cytotoxicity  (ADCC)  as  well  as  reduction  of  the 
S-phase cell cycle progression and decreased vascular 
epithelium growth factor mediated angiogenesis.3,12 
Other  potential  therapeutic  strategies  targeting  the 
HER2 signalling pathway that currently exist and/or 
in  development  include  tyrosine  kinase  inhibitors 
and anti-HER2 vaccines, respectively.13
The recommended loading dose for a three-weekly 
regimen  is  8  mg/kg  over  90-minute  followed  by 
6 mg/kg maintenance doses, which can be given over 
30 minutes if prior treatments were well   tolerated. 
For a weekly schedule, the recommended doses are 
4 mg/kg over 90 minute followed by 2 mg/kg over 
30  minute,  respectively.14  Trastuzumab  has  a  half 
life of six days with the weekly schedule doses and 
sixteen  days  with  the  3-weekly  one. An  adminis-
tration of a reloading dose is recommended if the 
planned maintenance dose is delayed or missed by 
more than a week. Trastuzumab does not appear to 
cross the intact blood brain barrier because of its large 
molecular size, and its disposition is not altered based 
on serum creatinine level.14
A number of trastuzumab-related side effects have 
been  described  which  may  require  close  monitor-
ing during therapy and/or discontinuation of treat-
ment  including  infusion  reactions,  cardiac  toxicity 
and pulmonary toxicity.3 The development of human 
antibodies against trastuzumab is rare but trastuzumab 
should  not  be  administered  in  patients  with  prior 
serious hypersensitivity reactions to trastuzumab or 
hypersensitivity reaction to Chinese hamster ovary 
cell proteins.14 Contraception is also recommended 
during and for six months after treatment of woman 
with child bearing potential, as trastuzumab exposure 
during  pregnancy  can  cause  oligohydramnios  with 
resultant pulmonary hypoplasia, skeletal malforma-
tions and neonatal death.14
clinical Trials of palliative 
Trastuzumab
The favourable benefit/risk profile associated with 
trastuzumab  for  the  treatment  of  HER2-positive 
metastatic breast cancer has been demonstrated in a 
number of clinical trials that examined trastusumab 
as  monotherapy  or  in  combination  with  chemo-
therapy, endocrine therapy and other HER2 targeted 
agents (Table 1).15–31 The impact of trastuzumab on palliative trastuzumab for breast cancer 
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Table 1. Landmark clinical trials of palliative trastuzumab in breast cancer.
study Year Design n Arms Efficacy outcomes
Trastuzumab monotherapy
vogel  
et al15
2002 phase 2 104  TZ (4 mg/kg loading → 2 mg/kg Qw or  
8 mg/kg loading → 4 mg/kg Qw)
rr 26% 
TTp 18.8 M (in responding patients) 
OS 24.4 M
Trastuzumab plus chemotherapy
Slamon  
et al16
2001 phase 3 469 Chemo Q3 w (A 60 mg/m2 + C 600 mg/m2 or  
E 75 mg/m2 + C 600 mg/m2 in anthra-naïve  
and p 175 mg/m2 in anthra-pretreated) +/- TZ  
(4 mg/kg loading → 2 mg/kg Qw)
rr 50% vs. 32% (P , 0.001) 
TTp 7.4 vs. 4.6 M (P , 0.001) 
OS 25.1 vs. 20.3 M (P = 0.001)
Marty  
et al17
2005 phase 2 186 Chemo (D 100 mg/m2 Q3 w) +/- TZ  
(4 mg/kg loading → 2 mg/kg Qw)
rr 61% vs. 34% (P , 0.001) 
TTp 11.7 vs. 6.1 M (P , 0.001) 
OS 31.2 vs. 22.7 M (P = 0.033)
Gasparini  
et al18
2007 phase 2 124 Chemo (p 80 mg/m2 Qw) +/- TZ  
(4 mg/kg loading → 2 mg/kg Qw)
rr 75% vs. 57% (P = 0.038) 
TTp 10.0 vs. 6.8 M (P = 0.076) 
OS not reached
Trastuzumab plus endocrine therapy
Kaufman  
et al25
2009 phase 3 207 Anastrozole (1 mg QD) +/- TZ  
(4 mg/kg loading → 2 mg/kg Qw)
rr 20% vs. 7% (P = 0.018) 
pFS 4.8 vs. 2.4 M (P = 0.002) 
OS 28.5 vs. 23.9 M (P = 0.325)
Huober  
et al26
2011 phase 2 57 Letrozole (2.5 mg QD) +/- TZ  
(4 mg/kg loading → 2 mg/kg Qw)
rr 27% vs. 13% (P = 0.31) 
TTp 3.3 vs. 14.1 M (P = 0.23) 
OS not reported
Trastuzumab beyond progression
von  
Minckwitz  
et al27,28
2009 phase 3 156 Cap (2500 mg/m2/day Days 1–14 Q3 w) +/- TZ  
(8 mg/kg loading → 6 mg/kg Q3 w)
rr 48% vs. 27% (P = 0.012) 
TTp 8.2 vs. 5.6 M (P = 0.034) 
OS 25.5 vs. 20.4 M (P = 0.257)
Trastuzumab plus other Her-2/neu targeted agents
Blackwell  
et al29
2010 phase 3 296 Lapatinib (1000 mg QD) + T  
(4 mg/kg loading → 2 mg/kg Qw) vs.  
Lapatinib (1500 mg QD)
rr 10% vs. 7% (P = 0.460) 
pFS 12 vs. 8 w (P = 0.008) 
OS 52 vs. 39 w (P = 0.106)
Baselga  
et al30
2011 phase 3 808 TZ (8 mg/kg loading → 6 mg/kg Q3 w) +  
D (75 mg/m2 Q3 w) +/- pZ  
(840 mg loading → 420 mg Q3 w)
rr 80% vs. 69% (P = 0.001) 
pFS 18.5 vs. 12.4 M (P , 0.001) 
OS interim analysis favours pZ arm
Others (trastuzumab-DM1)
Burris  
et al31
2011 phase 2 112 Trastuzumab-DM1 3.6 mg/kg Q3w rr 26% 
pFS 4.6 M 
OS not reported
Abbreviations: N, patient Number; TZ, Trastuzumab; A, Adriamycin; C, Cyclophosphamide; E, Epirubicin; D, Docetaxel; p, paclitaxel; v, vinorelbine; 
Carb, Carboplatin; Cap, Capecitabine; Anthra, Anthracycline; pZ, pertuzumab; Chemo, chemotherapy; AUC, Area under curve; Qw, weekly; QD, Daily; 
Q3 W, every 3 weeks; IHC, immunohistochemistry; FISH, florescence in situ hybridization; RR, response rate; TTP, time to progression; PFS, progression 
free survival; OS, overall survival; w, week; M, month.
metastatic breast cancer in these clinical trials has 
been examined through standard assessments of dis-
ease response rate (RR), progression free survival 
(PFS) and/or time to progression (TTP), and overall 
survival (OS).
palliative trastuzumab monotherapy
The activity of first line trastuzumab monotherapy in 
HER2-positive metastatic breast cancer was demon-
strated in a phase II trial, by Vogel et al, which random-
ized 114 patients to either trastuzumab 4 mg/kg loading 
followed by 2 mg/kg/week maintenance or 8 mg/kg 
loading followed by 4 mg/kg/week maintenance.15 The 
overall response rate for both cohorts was 26%, and 
trastuzumab was well tolerated. A sub group analy-
sis showed higher response rates of 35% and 34% in   
patients with IHC 3+ or FISH positive compared with   
0% and 7% in those with IHC 2+ or FISH negative 
tumors. Three  patients  (2.6%)  experienced  cardiac 
dysfunction, although one was not related to trastu-
zumab therapy. Based on these results, trastuzumab 
monotherapy was felt to be an important new first-line Jeyakumar and Younis
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option  for  patients  with  HER2-positive  metastatic 
breast cancer.15
palliative trastuzumab plus 
chemotherapy
The  benefits  of  palliative  trastuzumab  plus 
chemotherapy compared with chemotherapy alone for 
patients with metastatic HER2 positive breast cancer 
have  also  been  demonstrated  in  three  randomized 
clinical trials.16–18 Slamon et al, in a phase III trial, 
randomized  469  patients  with  HER2-positive 
metastatic  breast  cancer  to  chemotherapy  alone  or 
chemotherapy plus trastuzumab.16 The chemotherapy 
regimen  consisted  of  doxorubicin  or  epirubicin 
along with cyclophosphamide in anthracycline-naive 
patients  and  paclitaxel  in  anthracycline-pre-treated 
ones.  Trastuzumab  plus  chemotherapy  was 
associated with more favourable efficacy-outcomes, 
compared with chemotherapy alone, including higher 
overall response rate (50% vs. 32%; P , 0.001) and 
longer  duration  of  response  (9.1  vs.  6.1  months; 
P , 0.001) as well as longer time to progression (7.4 vs. 
4.6 months; P , 0.001) and improved overall survival 
(25.1 vs. 20.3 months; P = 0.01). Significant cardiac 
dysfunction, defined as New York Heart Association 
class 3 or 4, occurred in 27% of the patients treated 
with the anthracyclines plus trastuzumab compared 
with  8%  of  those  treated  with  the  anthracycline 
chemotherapy  alone  and  in  13%  of  the  patients 
treated  with  paclitaxel  plus  trastuzumab  compared 
with 1% of those treated with paclitaxel alone. Given 
these  results,  the  combination  of  anthracyclines 
and  trastuzumab  is  not  currently  recommended 
outside of clinical trials. Marty et al, in a phase II 
trial, randomized 186 patients to docetaxel alone or 
docetaxel plus trastuzumab.17 The chemotherapy plus 
trastuzumab arm was associated with more favourable 
efficacy-outcomes compared with the chemotherapy 
alone one including higher response rate (61% vs. 
34%; P = 0.0002) and longer duration of response 
(11.7 v 5.7 months; P = 0.009) as well as longer time 
to progression (11.7 vs. 6.1 months; P = 0.0001) and 
improved  overall  survival  (31.2  vs.  22.7  months; 
P  =  0.0325).  Higher  grade  3–4  neutropenia  (32% 
vs.  22%)  and  febrile  neutropenia  (23%  v  17%) 
however were observed in the combination compared 
with  the  docetaxel  alone  arm.  Gasparini  et  al,  in 
a  phase  II  trial,  also  randomized  124  patients  to 
paclitaxel alone or paclitaxel plus trastuzumab.18 The 
chemotherapy plus trastuzaumab arm was associated 
with higher response rate (75% vs. 57%; P = 0.038), 
longer  duration  of  response  (12.1  v  9.3  months; 
P = not reported) and time to progression (10.0 vs. 
6.8 months; P = 0.076) as well as improved overall 
survival (31.2 vs. 22.7 months; P = 0.0325) compared 
with the chemotherapy alone strategy. The median 
overall survival was not reached at the 16.6-month 
median follow-up reported. Both treatments were well 
tolerated and no cardiac toxicities were reported.
A number of clinical trials also examined outcomes 
associated  with  trastuzumab  in  combination  with 
other chemotherapeutic regimens and/or attempted to 
determine its optimal partner chemotherapy includ-
ing  taxanes,  vinca  alkaloids,  capecitabine,  gemcit-
abine and platinum salts.19–24 As an example, a phase 
III trial by Anderson et al randomized 284 patients 
with HER2-positive metastatic breast cancer to first-
line docetaxel plus trastuzumab or vinorelbine plus 
trastuzumab.19  No  statistically  significant  differ-
ences were observed between the two strategies with 
regards to time to progression or overall survival, but   
the former regimen was associated with more toxic-
ity and treatment discontinuations. Another phase III 
trial by Robert et al randomized 196 patients with 
HER2-positive  metastatic  breast  cancer  to  trastu-
zumab plus paclitaxel or trastuzmab plus paclitaxel 
and carboplatin.20 The triplet regimen was associated 
with higher response rate (52% vs. 36%; P = 0.04) 
and progression-free survival (10.7 vs. 7.1 months; 
P = 0.03) compared with the doublet one but no sta-
tistically significant improvement in overall survival 
(35.7 vs. 32.2 months: P = 0.76). Both treatment arms 
were well tolerated with however more hematologi-
cal toxicity occurring in the triplet regimen.
palliative trastuzumab plus  
endocrine therapy
The  combination  of  palliative  trastuzumab  and 
endocrine therapy for patients with endocrine-sensitive 
HER2-positive metastatic breast cancer was prospec-
tively examined in two randomized clinical trials com-
pared with endocrine therapy alone.25,26 Kaufman et al, 
in a phase III trial (TAnDEM study), randomized 207 
post-menopausal women with HER2 and hormone-
  receptor co-positive metastatic breast cancer to anas-
trozole  (1  mg  daily)  with  or  without    trastuzumab palliative trastuzumab for breast cancer 
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(4 mg/kg loading then 2 mg/kg weekly maintenance 
until  progression).25  Compared  with  the  endocrine 
therapy  alone  arm,  the  combination  treatment  was 
associated with significant improvement in the pri-
mary end point of progression-free-survival (4.8 vs. 
2.4 months, P = 0.0016) but no statistically significant 
difference in overall survival (28.5 vs. 23.9 months, 
P = 0.325). The lack of an observed survival benefit 
could have been due to the 70% cross-over from the 
anastrozole alone to the combination arm that occurred 
in the clinical trial after progression on the endocrine 
therapy alone arm. As expected, the combination arm 
was also associated with more frequent adverse events 
compared with the endocrine therapy alone one includ-
ing higher grade 3–4 toxicities (28% vs. 16%) and 
one patient experiencing heart failure. Houber et al, 
in a smaller phase II trial (eLEcTRA trial), also ran-
domized 57 post-menopausal women with HER2 and 
  hormone-receptor co-positive metastatic breast cancer 
to letrozole (2.5 mg daily) with or without trastuzumab 
(4 mg/kg loading then 2 mg/kg weekly maintenance 
until progression).26 The trial was closed prematurely 
due to low accrual. A non-statistically significant trend 
towards higher response rate and time to progression 
were noted in the combination strategy compared with 
the endocrine alone arm. No survival outcomes were 
reported. The small sample size of the study, however, 
precludes any firm conclusions with regards to the 
efficacy of the combination arm although the results 
were  concordant  with  those  observed  in  the  larger 
TAnDEM trial.
palliative trastuzumab beyond 
progression
The benefits of continuing trastuzumab beyond pro-
gression were prospectively examined in a phase III 
randomized  clinical  trial.27,28  Von  Minckwitz  et  al 
randomized  156  patients  who  progressed  on  first 
line trastuzumab to second line capecitabine alone 
or capecitabine plus continuing trastuzumab beyond 
progression. The latter strategy was associated with 
higher  response  rate  (48%  vs.  21%;  P  =  0.0115) 
and longer time to progression (8.2 vs. 5.6 months; 
P = 0.0338) compared with the former one but no sta-
tistically significant improvement in overall survival 
(25.5 vs. 20.4 months; P = 0.257) even after longer 
duration of follow-up.28 The role of palliative trastu-
zumab in patients with recurrent metastatic disease 
after adjuvant trastuzumab remains unclear, although 
it is not uncommonly offered to those with relapses 
occurring more than 12 months from completion of 
the adjuvant trastuzumab course.
palliative trastuzumab plus other 
targeted agents
Trastuzumab  has  also  been  used  in  combination 
with other HER2 targeted agents such as lapatinib 
(a tyrosine kinase inhibitor) and pertuzumab (an anti-
HER2 humanized monoclonal antibody that inhibits 
HER2 receptor dimerization) in second- and first-
line  settings,  respectively.29,30  Blackwell  et  al  ran-
domized 296 patients with HER2-positive metastatic 
breast cancer who progressed on prior trastuzumab-
continuing regimes, in a phase III trial (EGF104900 
trial), to lapatinib in combination with trastuzumab 
or lapatinib alone.29 The overall response rate was 
not  significantly  different  between  the  two  arms 
(10.3%  vs.  6.9%;  P  =  0.46),  but  the  combination 
strategy  was  associated  with  significant  improve-
ment in progression free survival (12 vs. 8 weeks; 
P = 0.008) and a trend towards improved overall 
survival (52 vs. 39 weeks; P = 0.106). There were 
more  frequent  diarrhea  in  the  combination  arm 
(P = 0.03) as well as higher incidence of symptom-
atic and asymptomatic cardiac events (2% and 3.4% 
vs. 0.7% and 1.4%, respectively). Baselga et al also 
randomized 808 patients with HER2-positive meta-
static breast cancer in a phase III trial (CLEOPATRA 
trial)  to  trastuzumab  and  docetaxel  plus  placebo 
(control group) or trastuzumab and docetaxel plus 
pertuzumab (pertuzumab group).30 The pertuzumab 
arm was associated with higher response rate (80% 
vs. 69%: P = 0.001) and longer progression-free sur-
vival (18.5 vs. 12.4 months; P , 0.001) compared 
with the control arm. An interim analysis of over-
all survival also showed a strong trend in favour of 
pertuzumab arm that awaits confirmation with lon-
ger follow-up. There were more frequent grade 3–4 
febrile neutropenia and diarrhea with no increased 
cardiac  toxicity  in  the  pertuzumab  arm  compared 
with the control group.
palliative trastuzumab-DM1 (T-DM1)
The  novel  antibody-drug  conjugate  trastuzumab-
DM1  (T-DM1)  combines  the  biologic  activity  of 
trastuzumab with targeted delivery of a potent anti-Jeyakumar and Younis
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microtubule  agent-DM1  to  the  HER2-positive 
metastatic breast cancer cells. In a single arm phase 
II trial by Burris et al, T-DM1 showed robust single-
agent activity in 112 heavily pre-treated patients with 
HER2-positive  metastatic  breast  cancer  who  had 
progression after prior HER2 directed therapy and 
chemotherapy.31 T-DM1 treated patients experienced 
a  remarkable  25.9%  objective  response  rate  and  a 
4.6  month  median  progression  free  survival.  The 
median duration of response has not been reached yet 
after a follow up of more than 12 months. Overall, 
T-DM1 was well tolerated with mostly grade 1 or 2 
adverse events and no dose-limiting cardiotoxicity. 
The  most  frequent  grade  $3  adverse  events  were 
hypokalemia (8.9%), thrombocytopenia (8.0%) and 
fatigue (4.5%). TDM-1 is currently being examined 
in a number of randomized clinical trials to ascertain 
its role in the management of HER2-positive meta-
static breast cancer.
In summary, anti-HER2 targeted therapy with tras-
tuzumab alone or in combination with other systemic 
therapeutic  agents  for  HER2-positive  metastatic 
breast  cancer  has  been  associated  with  significant 
though variable improvements in patient outcomes 
such as progression free survival and/or overall sur-
vival. Overall, trastuzumab appears to be well tol-
erated  although  on-therapy  monitoring  of  patients 
cardiac functions is recommended given its associated 
cardiac toxicity. Most notably, the novel antibody-
drug conjugate trastuzumab-DM1 (T-DM1) and the 
combination of trastuzumab plus other HER2 targeted 
agents (eg, lapatinib and pertuzumab) are promising 
strategies that will likely become new standards of 
care in the near future.
economic evaluations of palliative 
Trastuzumab
Trastuzumab is an expensive anti-cancer therapeutic 
that is associated with significant drug acquisition 
costs.32 These incremental costs, however, should be 
examined within the context of all clinical benefits 
and toxicities associated with trastuzumab therapy.33 
Indeed,  a  number  of  cost-effectiveness  analyses 
(CEA)/cost-utility  analyses  (CUA)  examined 
the  “value  for  money”  associated  with  palliative 
trastuzumab therapy in various scenarios (Table 2).34–
41  CEA  and  CUA  incorporate  disease  outcomes, 
treatment benefit/toxicity, costs and quality of life to 
compute the incremental costs per life-year (LY) or 
quality-adjusted life-year (QALY) gains, respectively 
associated  with  an  intervention/treatment.42 
CEA/CUE analyses rely on estimates of mean survival 
gains that incorporate life expectancy as opposed to 
median survival outcomes from clinical trials that 
involve  relatively  shorter  follow  up.42  CEA/CUE 
therefore  often  require  survival  modelling  beyond 
the relatively short follow-up in clinical trials and/
or extrapolation of survival gains from intermediate 
patient  outcomes  such  as  time  to  progression  or 
progression  free  survival.42  The  World  Health 
Organization  defines  favourable  cost-effectiveness 
based  on  the  Gross  Domestic  Product  (GDP)  per 
Table 2. Cost-effectiveness of palliative trastuzumab in breast cancer.
study Year Origin Drug costs (Us$)* Survival benefit cost-effectiveness (Us$)*
Trastuzumab monotherapy
NICE Appraisal34 2002 UK £5,300 (US$8,255) 8 months £19,000 (US$29,293)/QALY
Neyt et al35 2005 Belgium Nr 3.1 months €47,777 (US$61,780)/LY
Trastuzumab plus chemotherapy
NICE Appraisal34 2002 UK £15,500 (US$24,141) 10 months £37,500 (US$58,406)/QALY
Norum et al36 2005 Norway €39,454 (US$51,018) 8.4–3.7 months €63,137–162,417 
(US$81,643–210,021)/LY
poncet et al37–38 2008 France €14,102 (US$18,235) 17 months €15,370 (US$19,875)/LY
perez-Ellis et al39 2009 France €17,020 (US$22,009) 18 months €27,492 (US$35,550)/LY
Trastuzumab plus endocrine therapy
Fleeman et al40 2011 UK £35,702 (US$55,606) 8.0 months £69,000 (US$107,468)/QALY
Trastuzumab beyond progression
Matter-walstra et al41 2010 Swiss €18,756 (US$24,253) 5.5 months €98,329 (US$127,149)/QALY
notes: *Cost-effectiveness estimates in US$ are presented for comparison purposes only and should not be interpreted as the cost-effectiveness of 
trastuzumab in the USA. Exchange rates on January 20, 2012 (http://money.cnn.com/data/currencies/index.html).
Abbreviations: LY, Life Year; QALY, Quality Adjusted Life Year; Nr, Not reported; NICE, National Institute of Clinical Excellence.palliative trastuzumab for breast cancer 
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capita in various jurisdictions: highly cost effective 
(,GDP/capita),  cost-effective  (1–3  times   GDP/
capita) and not cost effective (.3 times GDP/capita).43 
In  North  America  and  the  UK,  interventions 
associated with cost-effectiveness below thresholds 
of  $50,000–100,000  and  £20,000–30,000  per 
QALY  gained  respectively  have  been  considered 
economically-favourable.44,45
palliative trastuzumab monotherapy
The cost-effectiveness of palliative trastuzumab mono-
therapy relative to standard chemotherapy alone was 
computed based on estimates of net survival benefits 
from  indirect  across-studies  comparisons,  as  there 
were no randomized trials of trastuzumab monother-
apy versus chemotherapy. A manufacturer (Roche)14 
economic evaluation, reviewed by the UK’ National 
Institute for Clinical Excellence (NICE), found a cost-
utility of £19,000 per QALY gained for trastuzumab 
monotherapy  relative  to  vinorelbine  chemotherapy 
with an 8 month mean survival benefit (2.6-quality 
adjusted months).34 As well, Neyt et al reported a cost-
utility of €47,777 per QALY gained in Belgium with 
a 3.1 month survival benefit for trastuzumab mono-
therapy relative to docetaxel chemotherapy.35
palliative trastuzumab plus 
chemotherapy
The cost-effectiveness of palliative trastuzumab plus 
chemotherapy relative to chemotherapy alone was also 
computed based on derivation of the net survival ben-
efits achieved with palliative trastuzumab. Analyses 
based on survival estimates derived from randomized 
clinical trials 34,36 reported less favourable “value for 
money” compared with those based on pragmatic / non 
randomized studies.37–39 NICE reviewed an economic 
evaluation  by  trastuzumab  manufacturer  (Roche)14 
that found a cost-effectiveness of £37,500 per QALY 
gained for trastuzumab plus chemotherapy relative to 
chemotherapy alone,34 based on a 10-month survival 
benefit  computed  from  one  pivotal  clinical  trial.16 
NICE appraisal committee however believed that the 
survival benefit in the model may have been underes-
timated and that the true cost-effectiveness is likely 
more favourable. Norum et al36 also reported an unfa-
vourable cost-effectiveness of €63,137 to €162,417 per 
QALY gained in Norway, based on 8.4 to 3.7 months 
survival benefit derived from the two relevant pivotal 
clinical  trials.16,17  Conversely,  Poncet  et  al  reported 
more  favourable  cost-effectiveness  of  €15,370  per 
QALY gained in France for trastuzumab in combi-
nation with chemotherapy relative to chemotherapy 
alone based on a 17 month survival benefit observed 
with trastuzumab in a non-randomized study.37,38 As 
well, Perez-Ellis also reported cost-effectiveness of 
€27,492 per QALY gained based on an 18 month sur-
vival benefit after compared with before introduction 
of trastuzumab in France.39 The 17 to 18 months net 
survival benefits observed in the latter two non ran-
domized studies however are far superior to the sur-
vival  benefit  observed  in  the  relevant  randomized 
clinical trials.16,17
palliative trastuzumab plus endocrine 
therapy
A health technology assessment by Fleeman et al 
reported a CU of £69,000 per QALY for trastuzumab 
plus  anastrozole  compared  with  anastrozole  alone 
based on an 8.0-month mean survival benefit derived 
from the relevant clinical trial (TAnDEM trial).40 As 
well, Fleeman et al also reported a CU of £225,000 
per QALY for lapatinib plus letrozole compared with 
letrozole alone based a 2-month mean survival ben-
efit from a clinical trial (EGF30008 trial). An eco-
nomic  evaluation  of  trastuzumab  plus  anastrozole 
compared with lapatinib plus letrozole, based on indi-
rect across-studies comparison, was not performed 
by Fleeman et al as it was considered inappropriate 
given the differences in these two trials cohorts.
palliative trastuzumab beyond 
progression
Matter-Walstra et al reported a CE of €98,329 per 
QALY  gained  for  capecitabine  plus  trastuzumab 
beyond progression versus capecitabine alone based 
on a computed 5.5-month mean survival   benefit.41   
As well, Le et al46 and Delea et al47 reported CUs 
for  lapatinib  plus  capecitabine  versus  capecit-
abine alone of US$166,113 and £77,993 per QALY 
gained based on 2.0 and 3.8 month survival benefits, 
respectively. Economic evaluations of trastuzumab 
plus capecitabine versus lapatinib plus capecitabine 
were also conducted, but should be viewed within the 
methodological limitations of indirect across-studies 
analyses.47,48 Younis et al found comparable up-front 
costs  (ie,  drug  acquisition  and  administration)  for Jeyakumar and Younis
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trastuzumab plus capecitabine relative to lapatinib 
plus  capecitabine  in  a  cost-minimization  analysis 
assuming clinical equivalence between the two strat-
egies,48 while Delea at al projected 0.4 month QALY 
gains and £107 fewer costs for the latter strategy (ie, 
economic dominance) in a cost-utility analysis.47
palliative trastuzumab plus other 
targeted agents
The  cost-effectiveness  of  combining  “trastuzumab-
based therapy” with other anti-HER2 targeted agents 
such as lapatinib or pertuzumab has not been evaluated 
to  date.  The  incorporation  of  these  novel  targeted 
agents  within  currently  utilized  trastuzumab-based 
strategies however is unlikely to provide good “value 
for money” at commonly utilized “cost-effectiveness” 
thresholds given their current and/or anticipated high 
drug acquisition costs as well as the magnitude of 
absolute survival gains associated with these strate-
gies in the relevant clinical trials.43–45
In summary, the cost-effectiveness of trastuzumab 
for  HER2-positive  metastatic  breast  cancer  is 
primarily driven by its clinical efficacy, in terms of 
incremental survival benefit, and trastuzumab costs. 
Indeed, palliative trastuzumab appears to be associated 
with more favourable “value for money” as first-line 
treatment with or without chemotherapy relative to 
continuing trastuzumab treatment beyond progression 
given  the  lower  magnitude  of  clinical  benefits 
(survival  gains)  observed  in  the  latter  compared 
with the former scenarios. It is also unlikely that the 
incorporation of other expensive albeit effective anti-
HER2 targeted therapies (eg, lapatinib or pertuzumab) 
with trastuzumab would prove to be cost-effective at 
the currently employed cost-effectiveness thresholds 
in various jurisdictions.
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